Opdivo is projected to lead the growth in renal cell carcinoma (RCC) market and be a market leader by 2023, according to a report by GlobalData.

Titled ‘PharmaPoint: Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2023‘, the report details how the data obtained from recently conducted trials have strengthened Opdivo’s position as an efficient drug for the treatment of metastatic renal cell carcinoma (mRCC).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The promising outlook for the drug is backed by encouraging survival outcome rates and objective response rates.

The drug is expected to have a high-patient uptake and consequently transform the RCC market, which is currently dominated by tyrosine kinase inhibitors and mTOR inhibitors.

"The drug is expected to have a high-patient uptake and consequently transform the RCC market, which is currently dominated by tyrosine kinase inhibitors and mTOR inhibitors."

A recent finding regarding Bristol-Myers Squibb’s Opdivo was presented at the American Society of Clinical Oncology conference held in May this year. The findings have labelled the drug as a new standard of care for mRCC.

The GlobalData report forecasts that the RCC market will expand to $3.6bn by 2023 from $2.1bn in 2013 mainly driven by the success of Opdivo. The recent trials measured the efficacy of Opdivo over its competitor Afinitor and have indicated a comparatively better tumour response with Opdivo, which is a positive finding as tumour response is correlated with patient survival.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The results of Phase I and II trials indicate that the survival of patients treated with the drug is promising in the long-term.

Dan Roberts, Ph.D., GlobalData’s senior analyst covering oncology and hematology, says: "These long-term results support the initial data published in the New England Journal of Medicine in September 2015, and further demonstrate that Opdivo significantly improves survival with a good quality-of-life."

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact